194 related articles for article (PubMed ID: 36285504)
1. S-1 eliminates MDSCs and enhances the efficacy of PD-1 blockade via regulation of tumor-derived Bv8 and S100A8 in thoracic tumor.
Nguyen NT; Mitsuhashi A; Ogino H; Kozai H; Yoneda H; Afroj T; Sato S; Nokihara H; Shinohara T; Nishioka Y
Cancer Sci; 2023 Feb; 114(2):384-398. PubMed ID: 36285504
[TBL] [Abstract][Full Text] [Related]
2. Bv8 Blockade Sensitizes Anti-PD1 Therapy Resistant Tumors.
Benguigui M; Vorontsova A; Timaner M; Levin S; Haj-Shomaly J; Deo A; Menachem R; Manobla B; Cooper TJ; Raviv Z; Shaked Y
Front Immunol; 2022; 13():903591. PubMed ID: 35874722
[TBL] [Abstract][Full Text] [Related]
3. Inhibiting myeloid-derived suppressor cell trafficking enhances T cell immunotherapy.
Sun L; Clavijo PE; Robbins Y; Patel P; Friedman J; Greene S; Das R; Silvin C; Van Waes C; Horn LA; Schlom J; Palena C; Maeda D; Zebala J; Allen CT
JCI Insight; 2019 Apr; 4(7):. PubMed ID: 30944253
[TBL] [Abstract][Full Text] [Related]
4. Infiltrating S100A8+ myeloid cells promote metastatic spread of human breast cancer and predict poor clinical outcome.
Drews-Elger K; Iorns E; Dias A; Miller P; Ward TM; Dean S; Clarke J; Campion-Flora A; Rodrigues DN; Reis-Filho JS; Rae JM; Thomas D; Berry D; El-Ashry D; Lippman ME
Breast Cancer Res Treat; 2014 Nov; 148(1):41-59. PubMed ID: 25270120
[TBL] [Abstract][Full Text] [Related]
5. Elevated levels of polymorphonuclear myeloid-derived suppressor cells in patients with glioblastoma highly express S100A8/9 and arginase and suppress T cell function.
Gielen PR; Schulte BM; Kers-Rebel ED; Verrijp K; Bossman SA; Ter Laan M; Wesseling P; Adema GJ
Neuro Oncol; 2016 Sep; 18(9):1253-64. PubMed ID: 27006175
[TBL] [Abstract][Full Text] [Related]
6. Targeting the crosstalk between cytokine-induced killer cells and myeloid-derived suppressor cells in hepatocellular carcinoma.
Yu SJ; Ma C; Heinrich B; Brown ZJ; Sandhu M; Zhang Q; Fu Q; Agdashian D; Rosato U; Korangy F; Greten TF
J Hepatol; 2019 Mar; 70(3):449-457. PubMed ID: 30414862
[TBL] [Abstract][Full Text] [Related]
7. Inhibition of myeloid-derived suppressive cell function with all-trans retinoic acid enhanced anti-PD-L1 efficacy in cervical cancer.
Liang Y; Wang W; Zhu X; Yu M; Zhou C
Sci Rep; 2022 Jun; 12(1):9619. PubMed ID: 35688951
[TBL] [Abstract][Full Text] [Related]
8. PMN-MDSCs accumulation induced by CXCL1 promotes CD8
Zhou X; Fang D; Liu H; Ou X; Zhang C; Zhao Z; Zhao S; Peng J; Cai S; He Y; Xu J
Cancer Lett; 2022 Apr; 532():215598. PubMed ID: 35176418
[TBL] [Abstract][Full Text] [Related]
9. E3 ligase TRIM28 promotes anti-PD-1 resistance in non-small cell lung cancer by enhancing the recruitment of myeloid-derived suppressor cells.
Liang M; Sun Z; Chen X; Wang L; Wang H; Qin L; Zhao W; Geng B
J Exp Clin Cancer Res; 2023 Oct; 42(1):275. PubMed ID: 37865804
[TBL] [Abstract][Full Text] [Related]
10. 5-FU mediated depletion of myeloid suppressor cells enhances T-cell infiltration and anti-tumor response in immunotherapy-resistant lung tumor.
Mathew AA; Zakkariya ZT; Ashokan A; Manohar M; Keechilat P; Nair SV; Koyakutty M
Int Immunopharmacol; 2023 Jul; 120():110129. PubMed ID: 37201402
[TBL] [Abstract][Full Text] [Related]
11. Histamine targets myeloid-derived suppressor cells and improves the anti-tumor efficacy of PD-1/PD-L1 checkpoint blockade.
Grauers Wiktorin H; Nilsson MS; Kiffin R; Sander FE; Lenox B; Rydström A; Hellstrand K; Martner A
Cancer Immunol Immunother; 2019 Feb; 68(2):163-174. PubMed ID: 30315349
[TBL] [Abstract][Full Text] [Related]
12. Regulation of ROS in myeloid-derived suppressor cells through targeting fatty acid transport protein 2 enhanced anti-PD-L1 tumor immunotherapy.
Adeshakin AO; Liu W; Adeshakin FO; Afolabi LO; Zhang M; Zhang G; Wang L; Li Z; Lin L; Cao Q; Yan D; Wan X
Cell Immunol; 2021 Apr; 362():104286. PubMed ID: 33524739
[TBL] [Abstract][Full Text] [Related]
13. Modified Bushen Yiqi formula enhances antitumor immunity by reducing the chemotactic recruitment of M2-TAMs and PMN-MDSCs in Lewis lung cancer-bearing mice.
Kong Q; Zhu H; Gong W; Deng X; Liu B; Dong J
J Ethnopharmacol; 2024 Jan; 319(Pt 1):117183. PubMed ID: 37739106
[TBL] [Abstract][Full Text] [Related]
14. Indoleamine 2,3-dioxygenase regulates anti-tumor immunity in lung cancer by metabolic reprogramming of immune cells in the tumor microenvironment.
Schafer CC; Wang Y; Hough KP; Sawant A; Grant SC; Thannickal VJ; Zmijewski J; Ponnazhagan S; Deshane JS
Oncotarget; 2016 Nov; 7(46):75407-75424. PubMed ID: 27705910
[TBL] [Abstract][Full Text] [Related]
15. PD-1 Signaling Promotes Tumor-Infiltrating Myeloid-Derived Suppressor Cells and Gastric Tumorigenesis in Mice.
Kim W; Chu TH; Nienhüser H; Jiang Z; Del Portillo A; Remotti HE; White RA; Hayakawa Y; Tomita H; Fox JG; Drake CG; Wang TC
Gastroenterology; 2021 Feb; 160(3):781-796. PubMed ID: 33129844
[TBL] [Abstract][Full Text] [Related]
16. Myeloid-Derived Suppressor Cells Impair B Cell Responses in Lung Cancer through IL-7 and STAT5.
Wang Y; Schafer CC; Hough KP; Tousif S; Duncan SR; Kearney JF; Ponnazhagan S; Hsu HC; Deshane JS
J Immunol; 2018 Jul; 201(1):278-295. PubMed ID: 29752311
[TBL] [Abstract][Full Text] [Related]
17. Asah2 Represses the p53-Hmox1 Axis to Protect Myeloid-Derived Suppressor Cells from Ferroptosis.
Zhu H; Klement JD; Lu C; Redd PS; Yang D; Smith AD; Poschel DB; Zou J; Liu D; Wang PG; Ostrov D; Coant N; Hannun YA; Colby AH; Grinstaff MW; Liu K
J Immunol; 2021 Mar; 206(6):1395-1404. PubMed ID: 33547170
[TBL] [Abstract][Full Text] [Related]
18. Anti-PD-1 antibody combined with chemotherapy suppresses the growth of mesothelioma by reducing myeloid-derived suppressor cells.
Otsuka K; Mitsuhashi A; Goto H; Hanibuchi M; Koyama K; Ogawa H; Ogino H; Saijo A; Kozai H; Yoneda H; Tobiume M; Kishuku M; Ishizawa K; Nishioka Y
Lung Cancer; 2020 Aug; 146():86-96. PubMed ID: 32526602
[TBL] [Abstract][Full Text] [Related]
19. Targeting Myeloid-Derived Suppressor Cell, a Promising Strategy to Overcome Resistance to Immune Checkpoint Inhibitors.
Hou A; Hou K; Huang Q; Lei Y; Chen W
Front Immunol; 2020; 11():783. PubMed ID: 32508809
[TBL] [Abstract][Full Text] [Related]
20. Targeting Myeloid-Derived Suppressor Cells to Enhance the Antitumor Efficacy of Immune Checkpoint Blockade Therapy.
Li X; Zhong J; Deng X; Guo X; Lu Y; Lin J; Huang X; Wang C
Front Immunol; 2021; 12():754196. PubMed ID: 35003065
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
